NCT02350309View on ClinicalTrials.gov

Study to Evaluate the Effect of 2 Dosage Strengths of Lemborexant (E2006) on a Multiple Sleep Latency Test in Participants With Insomnia Disorder

PHASE1CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

December 13, 2014

Primary Completion Date

April 21, 2015

Study Completion Date

April 21, 2015

Conditions
Insomnia Disorder
Interventions
DRUG

Lemborexant 5 mg

Lemborexant 5 mg tablet.

DRUG

Lemborexant 10 mg

Lemborexant 10 mg tablet.

DRUG

Lemborexant-matched placebo.

Lemborexant-matched placebo tablet.

DRUG

Flurazepam 30 mg

Flurazepam 30 mg capsule.

Trial Locations (2)

30342

Atlanta

41017

Crestview Hills

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT02350309 - Study to Evaluate the Effect of 2 Dosage Strengths of Lemborexant (E2006) on a Multiple Sleep Latency Test in Participants With Insomnia Disorder | Biotech Hunter | Biotech Hunter